



Published in final edited form as:

J Subst Abuse Treat. 2015 May ; 52: 78–81. doi:10.1016/j.jsat.2014.11.010.

Depressive Symptoms Among Patients Receiving Varenicline and Bupropion for Smoking Cessation

Arthur Hong, MD^a, Muhamad Y. Elrashidi, MD, MHA^b, Darrell R. Schroeder, MS^c, and Jon O. Ebbert, MD, MSc^b

^aDepartment of Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN 55905 USA

^bDivision of Primary Care Internal Medicine, Department of Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN 55905 USA

^cDivision of Biomedical Statistics and Informatics, Department of Health Sciences Research, Mayo Clinic, 200 First Street SW, Rochester, MN 55905 USA

Abstract

While the combination therapy of varenicline and sustained release bupropion (bupropion SR) for cigarette smoking cessation can increase smoking abstinence rates, it has also been associated with increases in self-reported depressive symptoms. We conducted an analysis of the Beck Depression Inventory, second edition (BDI-II), data completed by 505 patients from a large randomized clinical trial, evaluating the efficacy of 12 weeks of combination therapy (varenicline + bupropion SR) compared to varenicline alone. At medication treatment week 2 (1 week after target quit date [TQD]), increased depressive symptoms were observed in patients receiving combination therapy (effect estimate = 0.61, 95% CI [0.03, 1.19], $P=.039$) and those with a history of depression (effect estimate = 0.82, 95% CI [0.07, 1.57], $P=.033$). For treatment weeks 2 to 4, smokers with a history of depression on combination therapy had a greater decline in depressive symptoms compared to those on varenicline alone (effect estimate = -1.99 , 95% CI [-3.99 , 0.00], $P=.050$). After treatment week 4, no significant effects of treatment or depression history on BDI-II scores were observed. A history of depression did not moderate the efficacy of combination therapy for smoking abstinence. Our study suggests that for combination therapy with varenicline and bupropion SR, an increase in depressive symptoms over the first 2 weeks may be observed; however, the effects on depressive symptoms do not last beyond 4 weeks. We conclude that among smokers without active moderate or severe depression, the decision to use this combination treatment approach should not be based upon a self-reported history of depression.

© 2014 Elsevier Inc. All rights reserved.

Corresponding Author: Jon O. Ebbert, MD, MSc, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA, Telephone: 1 + (507) 266-1944, Facsimile: 1 + (507) 266-7900, ebbert.jon@mayo.edu.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Conflict of Interest: Arthur Hong, Muhamad Elrashidi, and Darrell Schroeder have nothing to disclose.

Keywords

depression; smoking cessation; varenicline; bupropion

1. Introduction

Despite reductions in the prevalence of cigarette smoking in Western nations over the last several decades, smoking continues to be a leading cause of preventable disease, disability, and death worldwide. Aggressive treatment approaches should continue to be explored to further reduce smoking rates.

Available evidence suggests that combination pharmacotherapy may increase smoking abstinence rates, compared to single-agent therapy. The combination treatment of bupropion sustained-release (SR)¹ and the nicotine patch has been shown to be more effective for increasing smoking abstinence than nicotine patch therapy alone (Jorenby et al., 1999). Also, the combination therapy of varenicline, a nicotinic acetylcholine receptor (nAChR) partial agonist (Coe et al., 2005), and bupropion SR is more effective than varenicline alone in promoting prolonged smoking abstinence among heavier and more dependent smokers (Ebbert et al., 2014). However, participants receiving combination therapy with bupropion SR and varenicline reported higher rates of depressive symptoms compared to participants randomized to varenicline alone (3.6% vs. 0.08%; $P=.03$). Adverse events were unprompted and self-reported, but these data raised important questions regarding the emergence of mood symptoms with the use of combination pharmacotherapy in patients attempting to quit smoking.

In order to evaluate the effect of combination pharmacotherapy on depressive symptoms among motivated smokers attempting to quit, we performed an analysis of depression scores from our clinical trial of combination pharmacotherapy with varenicline and bupropion SR. We sought to determine whether: 1) combination therapy worsens objective measures of depressive symptoms in smokers attempting to quit, and 2) combination therapy leads to different rates of prolonged abstinence among those with and without a history of depression.

2. Methods

2.1 Study Overview

Data were collected from participants in a randomized, double-blind, placebo-controlled, multicenter clinical trial (Ebbert, et al., 2014). This study evaluated the efficacy of combination therapy with bupropion SR and varenicline compared to varenicline and placebo in 506 cigarette smokers. Of these, 505 provided depression information. Eligible subjects were adult smokers without active moderate or severe depression or other active psychiatric illness, who had not previously attempted suicide, and who were not actively abusing other substances. A history of depression was self-reported at baseline visit.

¹Abbreviations: nAChR, nicotinic acetylcholine receptor; BDI-II, Beck Depression Inventory, second edition; SR, sustained release; TQD, target quit date

Specifically, the survey asked study participants, “Have you ever been diagnosed and or treated for depression? Yes/No.” Participants with BDI-II scores in the moderate to severe range (score >20) were excluded. Participants were randomized to varenicline and bupropion SR or varenicline and matching bupropion SR placebo. The medication was started the day after the baseline visit (week 0), and the target quit date (TQD) was on the eighth day of therapy. Both medication groups received treatment for a total of 12 weeks.

2.2 Depression Assessment

The Beck Depression Inventory, second edition (BDI-II) (Beck, Steer, & Brown, 1996) was used to assess depressive symptoms. Each question on the BDI-II is scored 0, 1, 2, or 3 with higher total scores indicating more severe depressive symptoms. The BDI-II was administered at baseline and then at regular intervals during the medication phase (weeks 2, 4, and 8) and during the follow-up phase (weeks 14 and 26).

2.3 Statistical Analysis

Baseline subject characteristics were compared across treatment arms (varenicline + bupropion SR vs. varenicline + placebo) and history of depression (depression vs. no depression) using 2-way analysis of variance (ANOVA) for continuous variables and binary or multinomial logistic regression for categorical variables. Post-baseline BDI-II scores were analyzed using analysis of covariance (ANCOVA), with treatment (varenicline + bupropion SR vs. varenicline + placebo) and history of depression (depression vs. no depression) as explanatory variables and baseline BDI-II score included as a covariate. An initial analysis that included all follow-up scores was performed using mixed linear models to account for the multiple post-baseline measures within subjects. Supplemental analyses were performed separately for each follow-up time point. Prolonged smoking abstinence at the end of treatment (week 12) was analyzed using logistic regression. Previous analyses from this trial have found that the effect of combination treatment varied with heaviness of smoking and was more effective for heavier smokers (Ebbert, et al., 2014). Therefore, in addition to an overall analysis, the end-of-treatment abstinence outcome was analyzed separately for light (< 19 cigarettes per day [cpd]) and heavy (≥ 20 cpd) smokers. In all cases, two-tailed tests were used, with *P* values < .05 denoting statistical significance.

3. Results

3.1 Participant Characteristics

Of the 506 study participants, 505 provided depression history information. Of these, 101 reported a history of depression. Treatment assignment was well balanced among those with depression (n = 50, varenicline + bupropion SR; n = 51, varenicline + placebo) and those without depression (n = 198 varenicline + bupropion SR; n = 206 varenicline + placebo). Baseline demographics and smoking history are presented in the Table, according to depression history and treatment assignment. Gender (*P*<.001) and marital status (*P*=.029) differed significantly between those with and without a history of depression; participants with a history of depression were more likely to be female and less likely to be married. No other characteristics differed significantly between depression groups, and no characteristics differed significantly between treatment groups.

3.2 BDI-II Scores

Baseline BDI-II was significantly higher ($P<.001$) in those with a history of depression, but was similar between the treatment groups ($P=.198$). Mean BDI-II scores over time are presented in our Figure, according to depression history and treatment. There were 470 (93%) participants who completed at least one post-baseline BDI-II assessment during the 6 month period following the start of medication. Of these 470, 7 had a BDI-II score ≥ 20 , indicating moderate or severe depression at some point between baseline and 26 weeks. Of these, 2 (1 varenicline + bupropion SR, 1 varenicline + placebo) had a history of depression, the other 5 (3 varenicline + bupropion SR, 2 varenicline + placebo) did not.

From an overall repeated measures analysis of post-baseline BDI-II scores, a significant ($P=.045$) treatment-by-depression-by-visit interaction effect was detected. For this reason, subsequent analyses were performed separately for each time period. For these analyses, the BDI-II score was the independent variable, while a history of depression and treatment assignment were the explanatory variables, and the baseline BDI-II score was a covariate. Two weeks after the start of medication (1 week after the TQD), significant main effects were detected for both history of depression (effect estimate = 0.82, 95% CI [0.07, 1.57], $P=.033$) and treatment (effect estimate = 0.61, 95% CI [0.03, 1.19], $P=.039$), indicating that both a history of depression and the combination therapy were associated with an increase in depressive symptoms. At week 4, a significant ($P=.032$) treatment-by-depression interaction was detected, indicating that the effect of combination treatment on the change in depressive symptoms was dependent on depression history.

Supplemental analyses were performed for each depression group to compare the change in BDI-II scores between treatment groups from week 2 to week 4. Among those with a history of depression, the change in BDI-II from week 2 to week 4 differed significantly between treatment groups. Participants with a history of depression receiving combination therapy experienced a significantly greater decline in depressive symptoms compared to those receiving varenicline alone (effect estimate = -1.99 , 95% CI [-3.99 , 0.00], $P=.050$). Among those without a history of depression, the change in BDI-II from week 2 to week 4 was similar between treatment groups (effect estimate = -0.19 , 95% CI [-0.80 , 0.43], $P=.55$). After week 4, there were no significant effects of treatment assignment or depression history on BDI-II scores.

3.3 Abstinence Rates

We assessed abstinence rates overall, as well as separately, for light and heavy smokers. In all cases, there was no evidence to suggest that a history of depression moderated the efficacy of combination treatment (treatment-by-history of depression interaction $P=.305$, .210, and .637 for overall, light, and heavy smokers, respectively). Among participants without a history of depression, prolonged smoking abstinence rates at week 12 were 53.7% with combination therapy and 37.5% with varenicline monotherapy among heavy smokers and 61.0% and 53.5% among light smokers, respectively. Among participants with a history of depression, heavy smokers had prolonged smoking abstinence rates at week 12 for combination therapy and varenicline of 36.0% and 28.2%, and light smokers had rates of 44.0% and 57.8%, respectively. As expected, combination treatment was associated with an

increased likelihood of abstinence among heavy smokers (main effect of combination treatment OR = 1.84, 95% CI [1.15, 2.93], $P=.011$), but not light smokers (OR = 1.13, 95% CI [0.65, 1.96], $P=.670$). For both light and heavy smokers, abstinence did not differ significantly between those with and without a history of depression (main effect of depression OR = 0.74, 95% CI [0.38, 1.45], $P=.386$ for light smokers; OR = 0.56, 95% CI [0.30 to 1.05], $P=.070$ for heavy smokers).

4. Discussion

We observed a transient increase in depressive symptoms with combination therapy at week 2, which was two weeks into therapy and one week of tobacco cessation. Beyond 4 weeks of treatment, combination therapy was not associated with a statistically significant effect on depressive symptoms. A history of depression did not change the effect of combination pharmacotherapy on smoking abstinence. The number of study participants with high BDI-II scores was comparable across both groups, and therefore the high scores were unlikely to be associated with a history of depression or combination treatment.

A transient increase in depressive symptoms with the combination therapy suggests an effect of bupropion SR. There is little in the literature describing the effects of antidepressants in the first week, but there is evidence of benefit within the first 2 weeks of therapy (Shiffman et al., 2000; Stewart et al., 2014), even though maximal clinical effects are noted 4 to 6 weeks after initiation (Posternak & Zimmerman, 2005). Previous research has shown that bupropion SR mitigates depressive symptoms stemming from nicotine withdrawal as soon as 14 days after initiation of treatment (Shiffman, et al., 2000). However, research has also suggested that nearly one-quarter of individuals on antidepressants may be “non-responders” and even do worse on therapy, which may explain this observed initial effect of bupropion SR (Gueorguieva, Mallinckrodt, & Krystal, 2011). This effect, however, is transient.

We observed that a history of a history of depression did not impact the effectiveness of combination pharmacotherapy on smoking abstinence. Reduced levels of circulating nicotine in smokers abstaining from smoking causes a cascade of withdrawal symptoms including irritability, restlessness, anxiety, and depressed mood (Benowitz, 2008) and may increase the risk of smoking relapse among those attempting to quit. Pharmacotherapy is a mainstay of tobacco dependence treatment partly because of its ability to mitigate the emergence of withdrawal symptoms such as depressed mood (Cinciripini et al., 2013; Ebbert, et al., 2014; Fiore MC, 2008). Bupropion SR has been shown to significantly increase smoking abstinence among smokers independent of a history of depression (Cox et al., 2004; Hayford et al., 1999). Varenicline, an nAChR partial agonist, reduces withdrawal symptoms and smoking satisfaction (Cahill, Stead, & Lancaster, 2012) and has been associated with reduced depressive symptoms (Cinciripini, et al., 2013). A trial investigating the differential effect of varenicline on those with, or without, a history of depression observed no difference in abstinence rates, and smokers with a history of depression did not report qualitatively worse neuropsychiatric symptoms, compared to those without a history of depression (McClure et al., 2009).

The main strength of our study is that we used a validated formal measure of depressive symptoms to further assess self-reported depressive symptoms (Ebbert, et al., 2014), and we had complete data on 505 of 506 participants in the previous trial. The major limitation of the current study is that the history of depression was based upon self-reports rather than objective evidence of depression history (i.e., chart review for clinical criteria). We also could not determine the independent effects of varenicline on depressive symptoms relative to placebo since all subjects received varenicline. However, a meta-analysis of 14 high-quality trials observed no increased risk for neuropsychiatric events with varenicline compared to placebo (Cahill, Stevens, Perera, & Lancaster, 2013). The generalizability of our findings to a general population of smokers may be limited because the trial in which this data was collected excluded active current depression; however, this is a common exclusion criterion among studies investigating smoking cessation pharmacotherapy (van der Meer, Willemsen, Smit, & Cuijpers, 2013).

Previous data have suggested that the use of combination therapy with varenicline and bupropion SR should be based on the heaviness of smoking (Ebbert, et al., 2014). Our findings support the safety of combination pharmacotherapy with varenicline and bupropion SR in smokers with or without a self-reported history of depression, in the absence of current moderate or severe depression.

Acknowledgements

the clinical trial was supported by NIH grant CA 138417 (principal investigator Jon O. Ebbert), the medication was provided by Pfizer. NIH and Pfizer had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

Dr. Ebbert reports serving as an investigator for clinical trials funded by Pfizer, receipt of consultancy fees from GlaxoSmithKline, research support from Pfizer, and research support from Orexigen and JHP Pharmaceuticals outside of the current study.

References

- Beck, AT.; Steer, RA.; Brown, GK. Manual for the Beck Depression Inventory-II. San Antonio, TX: Psychological Corporation; 1996.
- Benowitz NL. Neurobiology of nicotine addiction: implications for smoking cessation treatment. *The American journal of medicine.* 2008; 121 Suppl 1(4):S3–S10. [PubMed: 18342164]
- Cahill K, Stead LF, Lancaster T. Nicotine receptor partial agonists for smoking cessation. *Cochrane Database Syst Rev.* 2012; 4:CD006103. [PubMed: 22513936]
- Cahill K, Stevens S, Perera R, Lancaster T. Pharmacological interventions for smoking cessation: an overview and network meta-analysis. *Cochrane Database Syst Rev.* 2013; 5:CD009329. [PubMed: 23728690]
- Cinciripini PM, Robinson JD, Karam-Hage M, Minnix JA, Lam C, Versace F, Wetter DW. Effects of varenicline and bupropion sustained-release use plus intensive smoking cessation counseling on prolonged abstinence from smoking and on depression, negative affect, and other symptoms of nicotine withdrawal. *JAMA Psychiatry.* 2013; 70(5):522–533. [PubMed: 23536105]
- Coe JW, Brooks PR, Vetelino MG, Wirtz MC, Arnold EP, Huang J, O'Neill BT. Varenicline: an alpha4beta2 nicotinic receptor partial agonist for smoking cessation. *Journal of Medicinal Chemistry.* 2005; 48(10):3474–3477. [PubMed: 15887955]
- Cox LS, Patten CA, Niaura RS, Decker PA, Rigotti N, Sachs DP, Hurt RD. Efficacy of bupropion for relapse prevention in smokers with and without a past history of major depression. *J Gen Intern Med.* 2004; 19(8):828–834. [PubMed: 15242467]

- Ebbert JO, Hatsukami DK, Croghan IT, Schroeder DR, Allen SS, Hays JT, Hurt RD. Combination varenicline and bupropion SR for tobacco-dependence treatment in cigarette smokers: a randomized trial. *JAMA*. 2014; 311(2):155–163. [PubMed: 24399554]
- Fiore, MC.; J, C.; Baker, TB., et al. *Treating Tobacco Use and Dependence: 2008 Update*. Rockville, MD: U.S. Department of Health and Human Services. Public Health Service; 2008.
- Georgieva R, Mallinckrodt C, Krystal JH. Trajectories of depression severity in clinical trials of duloxetine: insights into antidepressant and placebo responses. *Arch Gen Psychiatry*. 2011; 68(12):1227–1237. [PubMed: 22147842]
- Hayford KE, Patten CA, Rummans TA, Schroeder DR, Offord KP, Croghan IT, Hurt RD. Efficacy of bupropion for smoking cessation in smokers with a former history of major depression or alcoholism. *Br J Psychiatry*. 1999; 174:173–178. [PubMed: 10211174]
- Jorenby DE, Leischow SJ, Nides MA, Rennard SI, Johnston JA, Hughes AR, Baker TB. A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation. *N Engl J Med*. 1999; 340(9):685–691. [PubMed: 10053177]
- McClure JB, Swan GE, Jack L, Catz SL, Zbikowski SM, McAfee TA, Javitz H. Mood, side-effects and smoking outcomes among persons with and without probable lifetime depression taking varenicline. *J Gen Intern Med*. 2009; 24(5):563–569. [PubMed: 19238488]
- Posternak MA, Zimmerman M. Is there a delay in the antidepressant effect? A meta-analysis. *J Clin Psychiatry*. 2005; 66(2):148–158. [PubMed: 15704999]
- Shiffman S, Johnston JA, Khayrallah M, Elash CA, Gwaltney CJ, Paty JA, DeVeugh-Geiss J. The effect of bupropion on nicotine craving and withdrawal. *Psychopharmacology (Berl)*. 2000; 148(1):33–40. [PubMed: 10663415]
- Stewart JW, McGrath PJ, Blondeau C, Deliyannides DA, Hellerstein D, Norris S, Blier P. Combination antidepressant therapy for major depressive disorder: speed and probability of remission. *J Psychiatr Res*. 2014; 52:7–14. [PubMed: 24485847]
- van der Meer RM, Willemsen MC, Smit F, Cuijpers P. Smoking cessation interventions for smokers with current or past depression. *Cochrane Database Syst Rev*. 2013; 8:CD006102. [PubMed: 23963776]

Highlights

- Assessment of varenicline + bupropion for quitting smoking on depressive symptoms
- Combination therapy increased depressive symptoms in the first 2 weeks
- No effect of therapy or past history of depression on symptoms after 4 weeks treatment
- Effectiveness of combination therapy not impacted by previous history of depression




Figure.
Change in Beck Depression Index II Scores

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

Table

Subject Characteristics

Characteristic	No History of Depression		History of Depression	
	Varenicline + Bupropion (N = 198)	Varenicline + Placebo (N = 206)	Varenicline + Bupropion (N = 50)	Varenicline + Placebo (N = 51)
Age, years	42.5 ± 12.1	41.7 ± 12.9	40.7 ± 12.7	42.5 ± 11.9
Gender, n (%)				
Female	81 (41)	89 (43)	32 (64)	37 (73)
Male	117 (59)	117 (57)	18 (36)	14 (27)
Race, n (%)				
White, non-Hispanic	188 (95)	193 (94)	45 (90)	49 (96)
Other	10 (5)	13 (6)	5 (10)	2 (4)
Marital status, n (%) Never				
married	55 (28)	58 (28)	18 (36)	11 (22)
Separated/Divorced	39 (20)	50 (24)	14 (28)	20 (39)
Married/Living as married	96 (48)	94 (46)	16 (32)	17 (33)
Widowed/other	8 (4)	4 (2)	2 (4)	3 (6)
Highest level of Education, n (%)				
High school graduate or less	45 (23)	53 (26)	9 (18)	14 (27)
Some college	127 (64)	109 (53)	29 (58)	28 (55)
College graduate or higher	26 (13)	44 (37)	12 (24)	9 (18)
Current smoking rate, cigarettes per day, mean±SD	20.0±7.4	19.8±7.8	17.7±6.9	19.2±8.3
Fagerström test for nicotine dependence (FTND) ^a , mean±SD	5.1±2.0	5.2±1.9	5.5±1.9	5.3±2.3
Duration of regular smoking, years, mean±SD	23.7±12.0	23.3±12.3	22.8±12.2	23.1±10.8
Age when started smoking, years, mean±SD	17.7±4.2	17.5±3.8	17.2±2.9	17.5±5.1
Serious quit attempt in past, n (%)				
No	22 (11)	18 (9)	6 (12)	1 (2)
Yes	176 (89)	188 (91)	44 (88)	50 (98)
Other tobacco users in household				
No	119 (60)	127 (62)	36 (72)	35 (69)
Yes	79 (40)	79 (38)	14 (28)	16 (31)

^aIn those without a history of depression, FTND was missing for 1 subject in each treatment group. In those with a history of depression, FTND was missing for 1 subject in the varenicline+bupropion SR group.